NCT00779740已完成3 期
Clinical Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 102
- 主要终点
- Change in 4 nasal symptom score (sneezing attack, rhinorrhea, nasal congestion, and nasal itching) from baseline at Week 2.
研究概览
简要总结
This is a multicenter, open-label, randomized, parallel group comparison study to verify the clinical equivalency of the old formulation (50 mcg as mometasone furoate [MF] in 50 μL of solution per spray) to the new formulation (50 mcg as MF in 100 μL of solution per spray) in patients with perennial allergic rhinitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of mongoloid race residing in Japan who satisfy all of the following criteria:
- •Patients having symptoms of perennial allergic rhinitis of moderate or severe degree, according to the classification of severity in the guidelines for the treatment of nasal allergy (partial revision) as well as a score of at least 4 in the score of 4 nasal symptoms, at the time of obtaining informed consent and during the pretreatment observation period.
- •Patients with a positive skin reaction test or specific IgE antibody quantitation, and with a positive cytological examination of nasal discharge (eosinophils) or nasal challenge test.
- •Outpatients who are at least 16 years of age at the time of informed consent obtained.
- •Male or female.
- •Patients who have the ability to give written informed consent (informed consent of the guardian must also be obtained for patients younger than 20 years).
- •Patients who can keep nasal allergy diary without fail.
排除标准
- •Patients with coexisting tuberculous disease or lower respiratory tract infection, or patients who, at the time of registration, have acute upper respiratory tract infection, acute pharyngitis, acute amygdalitis etc.
- •Patients with coexisting infections or systemic mycosis for which there are no effective antibiotics.
- •Patients with unhealed nasal septum ulcers, nasal surgery scar, or nasal trauma.
- •Patients with a history of hypersensitivity to steroids or mometasone furoate.
- •Patients who are pregnant or nursing or who may be pregnant and patients or patients' partners who desire to become pregnant during the study period.
- •Patients with severe hepatic, renal, cardiac, hematological disease, diabetes mellitus, hypertension or other serious coexisting diseases and whose general condition is poor.
- •Patients also allergic to pollen and the pollen release season occurs during the study period.
- •Patients with vasomotor rhinitis or eosinophilic rhinitis.
- •Patients with a nasal condition which may interfere with efficacy evaluation of the investigational product.
- •Patients who develop disease affecting nasal symptoms during the pretreatment observation period, i.e., during the 7 days before actual registration.
- •Patients who are participating or have participated in a clinical trial of another investigational drug within 120 days (4 months) before the day of the informed consent for this study.
- •Patients for whom the period of discontinuation of previous treatment effective for allergic rhinitis before the start of the investigational product administration is not sufficient or who cannot avoid its use.
- •Patients receiving specific desensitization therapy or nonspecific modulation therapy or who had just discontinued such therapies within 90 days (3 months) before providing consent to this study (unless such therapies are ongoing as maintenance therapy and had been started 180 days [6 months] or more before consent to this study).
- •Other patients judged inappropriate for study by the investigator or subinvestigator.
研究组 & 干预措施
Old Formulation Group
Active Comparator
干预措施: mometasone furoate (Drug)
New Formulation Group
Experimental
干预措施: mometasone furoate (Drug)
结局指标
主要结局
Change in 4 nasal symptom score (sneezing attack, rhinorrhea, nasal congestion, and nasal itching) from baseline at Week 2.
时间窗: After 2 weeks of treatment
次要结局
- Overall improvement(2 weeks)
- Laboratory tests(At 7 or more days before treatment start, and after 2 weeks of treatment)
- Change in each nasal symptom (sneezing attack, rhinorrhea, nasal congestion, and nasal itching).(After 2 weeks of treatment)
- Adverse events(From initial day of treatment until treatment is stopped.)
研究者
相似试验
已完成
1 期
Rosuvastatin Calcium Bioequivalence Study - FastHypercholesterolaemiaNCT01711749GlaxoSmithKline60
已完成
1 期
Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different FormulationsHealthyNCT02070796UCB Pharma SA50
已完成
1 期
A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy SubjectsHealthyNCT02019485Johnson & Johnson Pharmaceutical Research & Development, L.L.C.64
已完成
1 期
Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®HealthyNCT03659305R-Pharm80
已完成
1 期
Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy VolunteersAsthmaChronic Obstructive Pulmonary DiseaseNCT02968914AstraZeneca180